Kanabo Group Plc announced the launch of two new medical cannabis extract formulas for inhalation, designed specifically to fill a gap in the market for premium products for patients with severe pain. The new formulas, available in versions suitable for day and evening use, will be branded as a Kanabo-Noidecs partnership with LYPHE Group and used with the VapePod, containing high levels of THC, low CBD, and cannabis naturally derived terpenes. The launch will broaden Kanabo's vape offering to the market and is an additional step for the company to build a robust product offering to all eligible patients in the UK.

These new formulas will be available from next week to eligible patients via Dispensary Green pharmacy. Further to the above, Kanabo Group is committed to increasing patient access to prescribed medical cannabis in the UK by developing a new platform using its recently acquired UK subsidiary, The GP Service Ltd. The company announced that all the regulatory approvals have been obtained, and the testing stage of the platform has begun. Additional updates will be provided in due course.